ArticleMolecular biology reports2025
Development and clinical application of a low-cost high-resolution melting curve assay for CD36 gene variant screening in a chinese population.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD36 gene variants contribute to immune thrombocytopenia and are commonly observed in Asian populations. Detection of CD36 gene variants in clinical laboratories is currently limited, necessitating the development of a rapid and cost-effective screening method. Here, we presented a high-resolution melting curve assay for CD36 gene variant detection and evaluated its clinical applicability. MATERIALS AND
methodsWe designed a high-resolution melting (HRM)-based method for screening for CD36 gene variants and assessed its specificity, sensitivity, and repeatability via recombinant plasmids. We subsequently employed the HRM assay to analyze 758 clinical samples, with some results validated by DNA sequencing.
resultsThe HRM assay enabled the complete detection of CD36 gene variants, even at allele frequencies as low as 15%, with a detection limit of 1 pg of CD36 gene DNA. Among the 758 patients tested, 21 (2.77%) exhibited CD36 gene variants, with the most prevalent variant being 320-330delAC. The rates of CD36 gene variant detection were significantly higher in hematological patients (3.08%, 9/292), pregnant women (3.70%, 3/81), and organ transplant patients (4.27%, 8/187) than in the healthy control group (0.51%, 1/198). DISCUSSION: Our findings demonstrate that high-resolution melting analysis is a highly sensitive and specific method for identifying CD36 gene polymorphisms. This low-cost HRM assay is suitable for large-scale CD36 gene variant screening in clinical laboratories.
Indexed as
Identifiers
40775097What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.